While four big companies from the pharmaceutical segment have already reported their September quarter results, a handful remain
yet to report.
The following companies have reported their results for the September quarter:
-
Abbott Laboratories (NYSE: ABT) reported
adjusted EPS of $0.59 on revenue of $5.3 billion. While EPS topped by a penny, revenue came in line.
-
Eli Lilly and Co (NYSE: LLY) reported
adjusted EPS of $0.88, revenue of $5.19 billion and missed Street estimates.
-
Merck & Co., Inc. (NYSE: MRK) reported
GAAP EPS of $0.78 and adjusted EPS of $1.07 on revenue of $10.5 billion. Both EPS and revenue topped estimates.
-
Novartis AG (ADR) (NYSE: NVS) reported
core EPS of $1.23 and net sales of $12.13 billion. While EPS topped estimates, revenue fell shy of expectations.
Related Link: Citi
Starts Calithera Biosciences At Sell On Cash Burn And Lack Of Near-Term Catalysts
The following companies have yet to announce September quarter results:
-
AstraZeneca plc (ADR) (NYSE: AZN) is
scheduled to disclose its results on November 10. Analysts expect EPS of $0.74 on revenue of $5.91 billion.
-
Bristol-Myers Squibb Co (NYSE: BMY) is
slated to provide results on Thursday. Analysts expect EPS of $0.65 on revenue of $4.79 billion.
-
GlaxoSmithKline plc (ADR) (NYSE: GSK) will
announce its results on Wednesday. The Street is looking for an EPS of $0.74 on revenue of $8.86 billion.
-
Pfizer Inc. (NYSE: PFE) is scheduled to
report on November 1. The Street estimates EPS of $0.62 on revenue of $13.05 billion.
-
Sanofi SA (ADR) (NYSE: SNY) announces
results on Friday. Analysts expect EPS of $0.85 and revenue of $10.69 billion.
-
Shire PLC (ADR) (NASDAQ: SHPG) is
planning to announce results on November 1. The Street is looking for an EPS of $3.20 and revenue of $3.56 billion.
Full ratings
data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win
a $20 Amazon gift card!
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.